CRISPR gene editing for sickle cell disease: one disease, differentiated approaches

Autor: Lisa A Michaels, Bruce E Eaton

Publikováno v: Cell and Gene Therapy Insights. 7:851-856

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c02f24a8ab117a3e27a7a0d6bd005a5d
https://doi.org/10.18609/cgti.2021.116

Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: Results from an international laboratory study

Autor: Lilley Leong, Nikki Church, Lisa A. Michaels, I. Noerenberg, H.-F. Ulbrich, Steve Kitchen, Y. Katterle

Publikováno v: Haemophilia. 24:823-832

Introduction Discrepancies in the measurement of modified factor VIII (FVIII) products have been recognized, highlighting the need for adjustments in clinical laboratory practices to ensure effective monitoring of patients treated with these products

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b1400c61c97cd6b609dd0c814beb4e7
https://doi.org/10.1111/hae.13564

Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII

Autor: Mark T. Reding, Ingrid Pabinger, M. E. Eyster, Mingjun Wang, H. J. Shin, Michael Marcel Lederman, R. Walsch, M. Hardtke, Lone Hvitfeldt Poulsen, Lisa A. Michaels, Heng Joo Ng

Publikováno v: Reding, M T, Ng, H J, Poulsen, L H, Eyster, M E, Pabinger, I, Shin, H-J, Walsch, R, Lederman, M, Wang, M, Hardtke, M & Michaels, L A 2017, ' Safety and Efficacy of BAY 94-9027, a Prolonged-Half-Life Factor VIII ', Journal of Thrombosis and Haemostasis, vol. 15, no. 3, pp. 411-419 . https://doi.org/10.1111/jth.13597

BACKGROUND: BAY 94-9027 is a B-domain-deleted prolonged-half-life recombinant factor VIII (FVIII) conjugates in a site-specific manner with polyethylene glycol. OBJECTIVE: Assess efficacy and safety of BAY 94-9027 for prophylaxis and treatment of ble

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af9e38b5776a9062fc656696a5f8f150
https://doi.org/10.1111/jth.13597

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A:Results of the PROTECT VIII clinical trial

Autor: Camila Linardi, Lone Hvitfeldt Poulsen, Elena Santagostino, Shadan Lalezari, Lisa A. Michaels, Jonathan M. Ducore, Mark T. Reding, Heng Joo Ng

Publikováno v: Santagostino, E, Lalezari, S, Reding, M T, Ducore, J, Ng, H J, Poulsen, L H, Michaels, L A & Linardi, C C G 2019, ' Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A : Results of the PROTECT VIII clinical trial ', Thrombosis Research, vol. 183, pp. 13-19 . https://doi.org/10.1016/j.thromres.2019.08.023

Introduction Ensuring hemostasis during invasive procedures is a challenge in patients with severe hemophilia A. This analysis evaluated efficacy and safety of BAY 94-9027, an extended-half-life recombinant factor VIII (FVIII), in the surgical settin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbdccf9ade5b57081028bcbcef0b2d30
https://pure.au.dk/ws/files/210234115/Safety_and_efficacy_of_BAY_94_9027.pdf

An unusual presentation of May–Thurner Syndrome in a pediatric patient with a pelvic kidney

Autor: Jeffrey M. Eng, Lisa A. Michaels, Aaron R. Weiss, David M. Walor

Publikováno v: Journal of Pediatric Urology. 9:e72-e75

We report a case of an adolescent who presented with a deep vein thrombosis (DVT) and clinical findings consistent with May–Thurner Syndrome. Specific imaging demonstrated direct compression of the left common iliac vein by an overlying pelvic kidn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea396e69fa126c818ab26ae698952f59
https://doi.org/10.1016/j.jpurol.2012.08.014